In today’s session Alnylam Pharmaceuticals, Inc. (ALNY) registered an unusually high (513) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious ALNY increase. With 513 contracts traded and 23364 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: ALNY161216C00040000 closed last at: $2.8 or 16.7% up. About 383,826 shares traded hands. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 36.96% since March 16, 2016 and is downtrending. It has underperformed by 42.50% the S&P500.
Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on November, 14. They expect $-1.20 earnings per share, down 31.87% or $0.29 from last year’s $-0.91 per share. After $-1.05 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 14.29% negative EPS growth.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage
Out of 14 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 8 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 57% are positive. $184 is the highest target while $34 is the lowest. The $87 average target is 139.41% above today’s ($36.34) stock price. Alnylam Pharmaceuticals has been the topic of 29 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Janney Capital initiated the shares of ALNY in a report on Thursday, September 29 with “Neutral” rating. Goldman Sachs maintained it with “Neutral” rating and $34 target price in Thursday, October 6 report. The firm has “Mkt Perform” rating given on Thursday, October 6 by Leerink Swann. Jefferies initiated the stock with “Buy” rating in Friday, October 23 report. Credit Suisse initiated the stock with “Outperform” rating in Wednesday, January 20 report. The firm earned “Neutral” rating on Thursday, October 6 by JP Morgan. The firm has “Hold” rating by Stifel Nicolaus given on Thursday, October 6. The firm earned “Outperform” rating on Tuesday, May 3 by Leerink Swann. Jefferies maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Thursday, October 6 with “Buy” rating. JP Morgan maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Friday, August 5 with “Overweight” rating.
According to Zacks Investment Research, “Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.”
Insitutional Activity: The institutional sentiment decreased to 1.27 in Q2 2016. Its down 0.21, from 1.48 in 2016Q1. The ratio turned negative, as 31 funds sold all Alnylam Pharmaceuticals, Inc. shares owned while 60 reduced positions. 23 funds bought stakes while 93 increased positions. They now own 72.84 million shares or 2.29% more from 71.20 million shares in 2016Q1.
Blackrock Fund Advsr last reported 0.02% of its portfolio in the stock. Us Savings Bank De, a Minnesota-based fund reported 624 shares. Ladenburg Thalmann Service has invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Cap Fund Mgmt Sa has 49,622 shares for 0.03% of their US portfolio. Artisan Partnership holds 225,203 shares or 0.03% of its portfolio. Boston Private Wealth Ltd Liability Co accumulated 3,605 shares or 0.01% of the stock. Moreover, Jp Marvel Inv Advisors Limited Liability Company has 1.02% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 52,294 shares. Checchi Cap Advisers Limited Liability Company has invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Northern Tru Corporation has invested 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Meeder Asset Management holds 0.02% or 3,160 shares in its portfolio. California State Teachers Retirement Systems has invested 0.02% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Weiss Multi holds 0.02% or 3,645 shares in its portfolio. The Australia-based Commonwealth Natl Bank Of Australia has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). State Street Corp accumulated 2.20 million shares or 0.01% of the stock. Sei Invests last reported 42,654 shares in the company.
Insider Transactions: Since July 19, 2016, the stock had 1 insider buy, and 1 insider sale for $918,262 net activity. Shares for $1.95 million were sold by MARAGANORE JOHN. 27,900 shares with value of $1.03 million were bought by PYOTT DAVID E I on Thursday, October 13.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $3.24 billion. The Firm is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). It currently has negative earnings. It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs).
ALNY Company Profile
Alnylam Pharmaceuticals, Inc., incorporated on May 8, 2003, is a biopharmaceutical company. The Firm is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). The Company’s pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases.
More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “What’s Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure?” on October 07, 2016, also Fool.com with their article: “Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.” published on October 10, 2016, Fool.com published: “Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc.” on September 24, 2016. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Marketwatch.com and their article: “Alnylam Pharma stock plummets 45% after discontinuing drug on patient safety …” published on October 06, 2016 as well as Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of …” with publication date: October 06, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.